117 related articles for article (PubMed ID: 33740218)
1. Population Pharmacokinetics of Ibrutinib in Healthy Adults.
Al-Ghazawi M; Saleh MI; Najib O; Salem I; Najib N
Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):405-413. PubMed ID: 33740218
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Gallais F; Ysebaert L; Despas F; De Barros S; Dupré L; Quillet-Mary A; Protin C; Thomas F; Obéric L; Allal B; Chatelut E; White-Koning M
Clin Pharmacokinet; 2020 Sep; 59(9):1171-1183. PubMed ID: 32328976
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
4. Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
Tapaninen T; Olkkola AM; Tornio A; Neuvonen M; Elonen E; Neuvonen PJ; Niemi M; Backman JT
Clin Transl Sci; 2020 Mar; 13(2):345-351. PubMed ID: 31664782
[TBL] [Abstract][Full Text] [Related]
5. Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
de Vries R; Smit JW; Hellemans P; Jiao J; Murphy J; Skee D; Snoeys J; Sukbuntherng J; Vliegen M; de Zwart L; Mannaert E; de Jong J
Br J Clin Pharmacol; 2016 Feb; 81(2):235-45. PubMed ID: 26382728
[TBL] [Abstract][Full Text] [Related]
6. Extrahepatic metabolism of ibrutinib.
Rood JJM; Jamalpoor A; van Hoppe S; van Haren MJ; Wasmann RE; Janssen MJ; Schinkel AH; Masereeuw R; Beijnen JH; Sparidans RW
Invest New Drugs; 2021 Feb; 39(1):1-14. PubMed ID: 32623551
[TBL] [Abstract][Full Text] [Related]
7. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M
Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
Bonate PL; Floret S; Bentzen C
Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
Yang S; Lukey P; Beerahee M; Hoke F
Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
[TBL] [Abstract][Full Text] [Related]
15. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
[TBL] [Abstract][Full Text] [Related]
17. Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.
Chaturvedula A; Fossler MJ; Hendrix CW
J Clin Pharmacol; 2014 Feb; 54(2):150-60. PubMed ID: 24203458
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]